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Letters to the Editorfunction is key to understanding the
working mechanisms of SVR
and explain the somewhat variable re-
ported success.3,4 The pathophysiology
of the selected patients, the details
of the surgical intervention, such as the
amount of volume reduction, the applied
additional surgical interventions, and the
interactions between these factors, all
could ‘‘tip the balance.’’ Identification
and quantification of the specific effects
of SVR on the various components of
cardiovascular function ultimately
might help to select optimal candidates
and potentially to further optimize
this intervention to put more weight on
the positive side and lift the negative
side.
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XENOTRANSPLANTATION
TECHNOLOGY PROVIDES
MATERIALS FOR IMPROVED
BIOPROSTHETIC HEART
VALVES
To the Editor:
In their recent article published in
the Journal,McGregor and colleagues1238 The Journal of Thoracic and Cprovide further evidence that biopros-
thetic heart valves (BHVs) constructed
from wild-type (genetically unmodi-
fied) porcine or bovine sources are
less than optimal, as previously re-
ported and discussed by others.2-5
Because of the expression of
Gala1,3Gal (Gal), and possibly other
porcine or bovine antigens, they
are susceptible to inflammation,
calcification, and failure.
The model used by McGregor and
colleagues is not ideal. (1) The pig tis-
sue was implanted into the subcutane-
ous tissue of the recipient, and
therefore was not in direct contact
with blood (in which anti-pig anti-
bodies circulate). (2) The pig tissue
was coated with anti-Gal antibody be-
fore implantation, rather than being
continually exposed to anti-pig anti-
bodies (which are continually being
produced by a human recipient, which
is not the case when a Gal-positive an-
imal, eg, rat or rabbit, is used as the
recipient of the graft). (3) The pig graft
was exposed only to anti-Gal anti-
bodies and not to other human
anti-pig (anti–non-Gal) antibodies.
Nevertheless, despite these limita-
tions, the authors clearly demonstrate
the detrimental effect of using porcine
or bovine tissues that are susceptible to
human anti-Gal antibodies and make
a strong case that tissues from a1,3-
galactosyltransferase gene-knockout
(GT-KO) pigs, which do not express
Gal, should be the sources of BHVs,
as suggested previously.2-5
As the authors point out, GT-KO
mice and pigs, both of which make
anti-Gal antibodies (and therefore
mimic humans in this respect), are
now readily available for future exper-
imental studies. However, despite the
reservations the authors express, the
pig-to-nonhuman primate model
would clearly be the optimal model.
Indeed, studies have already clearly
shown that GT-KO porcine tissues
elicit a weaker inflammatory response
than wild-type (unmodified) pig tis-
sues when implanted into nonhuman
primates.6ardiovascular Surgery c July 2011However, why limit clinical trials to
the use of tissues from GT-KO pigs,
when GT-KO pigs that express one or
more complement-regulatory proteins
(eg, CD46, CD55) are also available?
The expression of a complement-
regulatory protein would almost cer-
tainly protect the tissues further from
immune injury, particularly because
there will also be a response to non-
Gal antigens. Furthermore, pigs are
also becoming available that express
human anti-inflammatory or antithrom-
botic transgenes (eg, CD39 or thrombo-
modulin), which are likely to provide
even greater protection. It can realisti-
cally be concluded that survival of
BHVs from suchgenetically engineered
pigs would be extended significantly.
The biggest hurdle to the use of ge-
netically engineered pigs as sources
of BHVs, despite compelling reasons
to do so, would seem to be related to
business economics. The cost of ge-
netically engineered pigs would be
considerably more than the minimal
cost of wild-type pigs. As pointed
out previously,5 if a BHV from a ge-
netically engineered pig functioned
in the patient for a significantly longer
period of time, this would clearly be
in the patient’s interests, but it is un-
likely to be to the economic advan-
tage of the company supplying the
BHV. The cost of the BHV would be
significantly greater, and the need
for replacement would be signifi-
cantly reduced.
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We thank Manji and colleagues for
their comments on our article, ‘‘Car-
diac xenotransplantation technology
provides materials for improved bio-
prosthetic heart valves.’’ There is
growing consensus that ectopic calci-
fication, including calcification of bio-
prosthetic heart valves, may occur in
response to local inflammatory reac-
tions.1 Our research, which builds on
earlier fundamental findings that
show glutaraldehyde fixed biopros-
thetic materials are not totally immu-
nologically inert,2,3 sought to identify
a potential clinically relevant
mechanism for such inflammation
and suggests that anti-Gal antibody
binding to bioprosthetic materials
may be one such signal. As indicated
in the article, our work is consistent
with the clinical histopathology of ex-
planted porcine valves derived from
left ventricular assist devices and
extends the earlier observations that
antibody from sensitized serum could
accelerate calcification.4 This work
and our earlier study5 using Gal-
positive and Gal-deficient fixed por-
cine pericardium show that naturalThe Journalpreformed anti-Gal antibody is suffi-
cient to accelerate the calcification
process in the subcutaneous implant
model. This suggests, but does not
conclusively prove, that a preformed
anti-Gal antibody–mediated inflam-
matory response may occur soon after
implantation and that such an
antibody-mediated inflammation may
initiate an innate immune response
that furthers calcification of the de-
vice. The a1,3-galactosyltransferase
gene-knockout (GT-KO) pig, which
makes anti-Gal antibody, is an appro-
priate model to test this hypothesis
because implantation of Gal-positive
bioprosthetic materials would repre-
sent an allogeneic implant that differs
from the recipient only by the pres-
ence of aGal sugar. Our results sup-
port the use of GT-KO tissues for
valve development as a means to de-
bulk the major antigen. It may also
be of interest to determine if the early
inflammatory response is blocked,
whether other clinical modalities that
block antibody-induced inflammation
could further forestall degeneration
of bioprosthetic heart valves.
In their letter, Manji and colleagues
suggest that additional genetic modifi-
cation of bioprosthetic materials,
including complement regulatory pro-
teins and antithrombotic functions,
might be incorporated to further pre-
vent valve degradation. We agree that
incorporation of these functions in liv-
ing tissues may help to prevent rejec-
tion of xenogeneic organs or tissues.
The high level of glutaraldehyde fixa-
tion used in the preparation of biopros-
thetic valves, however, would likely
inactivate the function of these pro-
teins, thereby eliminating any potential
protection to the bioprosthetic valve.
We agree that under the current reg-
ulations the cost of bioprosthetic heart
valves from genetically modified
sources would likely be increased
compared with wild-type pigs. It
seems likely that the level of biosecur-
ity, which significantly affects the cost
of production, needed for fixed valve
tissue would be lower than the highof Thoracic and Cardiovascular Surgelevel of biocontainment required by
regulatory agencies to produce live
tissues and organs for xenotransplan-
tation. If genetically modified valves
have greater durability, then the addi-
tional cost of the valve will be offset
by the benefit to the patient and use
in a potentially expanded younger pa-
tient population and might be further
offset by future regulatory changes
governing the disposition of geneti-
cally modified animal tissues.
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